Australia-based biotech PolyActiva receives AUS$9.2m ($9.5m) series B from a consortium of new and existing investors to develop glaucoma and osteoarthritis treatments.
PolyActiva, a joint venture biotech between the Bionic Ear Institute, the Centre for Eye Research Australia, and the Commonwealth Scientific and Industrial Research Organisation (CSIRO), has raised AUS$9.2m ($9.5m) in a series B round that saw new investors join existing backer the Medical Research Commercialisation Fund (MRCF). The latest round also saw investment from the…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
